Detail of "169590-41-4"

Reference

Compositions of a cyclooxygenase-2 selective inhibitor and an angiotensin II receptor antagonist for the treatment of central nervous system damage

Compositions of a cyclooxygenase-2 selective inhibitor and an angiotensin II receptor antagonist for the treatment of central nervous system damage. Stephenson, Diane T.; Taylor, Duncan P. (Pharmacia Corporation, USA). PCT Int. Appl. WO 2005007156 A1 27 Jan 2005, 161 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. CLASS: ICM: A61K031-41. ICS: A61K031-415; A61K031-135. 169590-41-4 and 139481-59-7 are also in the experiment. APPLICATION: WO 2004-US22190 8 Jul 2004. PRIORITY: US 2003-2003/PV486775 10 Jul 2003. DOCUMENT TYPE: Patent CA Section: 1 (Pharmacology) The present invention provides compns. and methods for the treatment of central nervous system damage in a subject. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic condition or a central nervous system traumatic injury comprising the administration to a subject of an angiotensin II receptor antagonist in combination with a cyclooxygenase-2 selective inhibitor. Examples include evaluation of COX-1 and COX-2 activity in vitro, measuring platelet aggregation and platelet activation markers, and global cerebral ischemia. .

Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage

Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage.Several substances are used for example 266320-83-6 and 169590-41-4 which are their cas registry numbers. Stephenson, Diane T.; Taylor, Duncan P. (Pharmacia Corporation, USA). PCT Int. Appl. WO 2004103283 A2 2 Dec 2004, 154 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. CLASS: ICM: A61K. APPLICATION: WO 2004-US14983 13 May 2004. PRIORITY: US 2003-2003/PV470359 14 May 2003. DOCUMENT TYPE: Patent CA Section: 1 (Pharmacology) The present invention provides compns. and methods for the treatment of central nervous system damage in a subject. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic condition or a central nervous system traumatic injury comprising the administration to a subject of a central nervous system stimulant in combination with a cyclooxygenase-2 selective inhibitor. The combination therapy was evaluated with tests such as COX-1 and COX-2 activity in vitro, measuring platelet aggregation and platelet activation markers, and whole blood flow cytometry. .